10 recruiting, 5 completed, 2 not yet recruiting, 2 terminated. 20 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Recruiting 10, Completed 5, Not yet recruiting 2, Terminated 2, Active not recruiting 1 |
| Phase 1 | 4 | Recruiting 3, Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Immune Checkpoint Inhibitor: new trials by email Literature Review of Immune Checkpoint Inhibitor trials Research Report on Immune Checkpoint Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial Ruxolitinib, Pembrolizumab - Carcinoma, Squamous Cell of Head and Neck HNSCC | Phase 2 | Not yet recruiting | University Hospital, Basel, Switzerland | 66 | 2026-11-01 | 2026-10-20 |
| NK Cells Plus ICI for SCLC Maintenance Allogeneic Natural Killer Cells, Immune Checkpoint Inhibitor - Small Cell Lung Cancer | Phase 2 | Recruiting | Tianjin First Central Hospital | 42 | 2026-08-01 | 2026-08-12 |
| Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting Becotatug vedotin (MRG003) - ESCC | Phase 2 | Recruiting | The First Affiliated Hospital of Bengbu Medical University | 38 | 2026-05-01 | 2026-10-23 |
| [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer Best Practice, Biopsy of Breast, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Washington | 22 | 2026-02-26 | 2026-05-19 |
| Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors DT-7012, Immune checkpoint inhibitor - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Domain Therapeutics Australia Pty Ltd | 125 | 2025-06-25 | 2026-05-06 |
| Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 228 | 2025-06-01 | 2025-06-26 |
| Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma Stereotactic Body Radiotherapy (extracranial) concurrent with Immunotherapy, Immunotherapy alone - Melanoma Metastatic | Phase 2 | Recruiting | Melanoma Institute Australia | 129 | 2025-03-06 | 2026-05-07 |
| ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI Immune checkpoint inhibitor - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Peking Union Medical College Hospital | 27 | 2024-08-09 | 2024-11-07 |
| Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer Immunotherapy, Targeted therapy, Hyperthermia - Metastatic Castration-resistant Prostate Cancer (CRPC) | Phase 2 | Recruiting | Pengyuan Liu | 60 | 2024-01-01 | 2024-02-08 |
| Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer Immune checkpoint inhibitor, FOLFOX regimen - Locally Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 170 | 2023-11-01 | 2025-11-28 |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies IMSA101, Immune checkpoint inhibitor, PULSAR - Oligoprogressive | Phase 2 | Terminated | ImmuneSensor Therapeutics Inc. | 16 | 2023-07-07 | 2026-05-15 |
| Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC IMSA101, Immune checkpoint inhibitor, PULSAR - Oligometastatic Disease | Phase 2 | Terminated | ImmuneSensor Therapeutics Inc. | 6 | 2023-06-28 | 2025-10-20 |
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI CP-506, Carboplatin, Immune checkpoint inhibitor - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Recruiting | Maastricht University Medical Center | 126 | 2023-05-30 | 2025-10-07 |
| Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Nivolumab - Esophageal Cancer | Phase 2 | Active not recruiting | Erasmus Medical Center | 77 | 2022-09-29 | 2025-02-13 |
| Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Surufatinib, Anti-PD-1/L1 - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Completed | Hutchison Medipharma Limited | 21 | 2022-09-27 | 2025-08-29 |
| Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer Sintilimab, Short-course radiotherapy, CAPOX/mFOLFOX - Rectal Neoplasms Malignant, Radiotherapy | Phase 2 / Phase 3 | Not yet recruiting | Chinese Academy of Medical Sciences | 588 | 2022-08-06 | 2022-08-02 |
| Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany), tislelizumab (BeiGene, China) combined with PD-1 inhibitor - Gastrointestinal Tumor | Phase 1 / Phase 2 | Completed | Pengyuan Liu | 18 | 2020-06-01 | 2023-09-05 |
| Sequential TACE and SBRT Followed by ImmunoTherapy for Downstaging HCC for Hepatectomy TACE, SBRT, Immune Checkpoint Inhibitor - HCC | Phase 2 | Completed | The University of Hong Kong | 33 | 2019-03-01 | 2024-05-09 |
| CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors Nivolumab or Pembrolizumab or Atezolizumab, SBRT - Urothelial Carcinoma, Melanoma | Phase 2 | Completed | University Hospital, Ghent | 99 | 2018-03-09 | 2024-01-23 |
| Priming Immunotherapy in Advanced Disease With Radiation Immune checkpoint inhibitor, Radiation Therapy - Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | John L. Villano, MD, PhD | 76 | 2017-10-26 | 2026-03-11 |
Carcinoma, Non-Small-Cell Lung (4) · Head and Neck Neoplasms (3) · Carcinoma, Renal Cell (2) · Hyperthermia (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Digestive System Neoplasms (1) · Esophageal Neoplasms (1) · Liver Neoplasms (1) · Melanoma (1) · Ovarian Neoplasms (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · ImmuneSensor Therapeutics Inc. (2) · Pengyuan Liu (2) · Chinese Academy of Medical Sciences (1) · Domain Therapeutics Australia Pty Ltd (1) · Erasmus Medical Center (1) · Hutchison Medipharma Limited (1) · John L. Villano, MD, PhD (1) · Maastricht University Medical Center (1) · Melanoma Institute Australia (1) · Peking Union Medical College Hospital (1) · The First Affiliated Hospital of Bengbu Medical University (1) · The University of Hong Kong (1) · Tianjin First Central Hospital (1) · University Hospital, Basel, Switzerland (1)
China (9) · United States (5) · Australia (2) · Belgium (2) · Netherlands (2) · Canada (1) · France (1) · Germany (1) · Hong Kong (1) · Spain (1) · Switzerland (1)
Patrick Widhelm (2) · Angela Hong (1) · Anna Brandt, PD Dr. (1) · Bianca Mostert, MD (1) · Chi Leung Chiang, Chiang (1) · Henk Verheul, MD, PhD (1) · Irene Brana, MD, PhD (1) · Jennifer Specht, MD (1) · Jing Huang (1) · John Villano, MD, PhD (1) · Jun Chen (1) · Loes Jansen, MD (1) · Minjiang Chen, MD. (1) · Nuria Kotecki, MD, PhD (1) · Piet Ost, PhD (1)
PMID 33962592, PMID 36529152, PMID 37315579, PMID 37410476, PMID 39020518, PMID 40845854, PMID 41120904